ABSTRACT
We report a case of a 19-year-old female with multisystemic inflammatory syndrome that was associated with the novel coronavirs disease 2019 (COVID-19), which manifested as serious illness that occurred four weeks after COVID-19 infection. Her clinical manifestations involved multiple organ systems including high-grade fever with shock syndrome, pulmonary edema, myopericarditis with pericardial effusion, hepatitis, generalized maculopapular rash, and several elevated inflammatory markers. She was treated with human immunoglobulin, methylprednisolone, acetylsalicylic acid, enoxaparin, and empirical antibiotics. She required a 2-week hospitalization and was discharged after improvement of clinical symptoms and normalization of inflammatory markers. A day prior to discharge, an echocardiography was done and it showed normal ventricular function and no coronary aneurysmal dilation.
ABSTRACT
This study presents the results of the examination of potential donors of blood and its components for immunoglobulins M and G to patients with coronavirus disease 2019 (COVID-19) living in St. Petersburg. A total of 6782 people aged 18-24 years were evaluated, which accounted for 2.07% of the region's population (326 760 people) of this age group. The study was carried out in the spring and autumn of 2020. A negative result (absence of antibodies) was obtained in 93.5% of the participants. The rates of immunoglobulins M and M + G were 0.58% and 4.18%, respectively, in the spring and autumn. Moreover, the number of participants who had immunoglobulins M and G + M in the autumn period was four times higher than the indicators of the spring period, which indicated greater infection activities in the population during this period. This is most likely due to the active movement of the population in the summer. When comparing the rates of COVID-19 infection and the frequency of occurrence in donors of the same age, markers of human immunodeficiency virus 1 and 2 and hepatitis B and C in 2020 (0.024, 0.012 and 0.13%, respectively) indicate the urgency of the problem of donor selection during blood services, especially during a difficult epidemiological situation because of COVID-19. Along with organizational measures for the selection of donors (e.g., attracting individuals from organized groups in which there are no signs of an unfavorable epidemiological situation to donation), mandatory testing of potential donors for immunoglobulins M and G should be considered.
ABSTRACT
Introduction: COVID-19 caused by SARS coronavirus two has halted life across the globe since its emergence in December 2019. Most of the infected persons are asymptomatic or have mild symptoms. Serosurvey is vital for the estimation of the burden of infection. In this context, our study objective is to estimate the Seroprevalence of SARS CoV 2 IgG among the first-year medical students after the first wave in February 2021. Method: A cross-sectional study was conducted among the first-year medical students of Veer Surendra Sai Institute of Medical Sciences and Research. All the students were enrolled, and their data & serum sample was collected. Serum samples were tested for the presence of Anti-Spike IgG. Data were analyzed by using appropriate statistical tests.
ABSTRACT
Objective To describe the diagnosis and treatment of a patient with severe novel coronavirus pneumonia, and to improve the understanding and management of clinicians on novel coronavirus pneumonia. Methods The onset, development, treatment and outcome of a patient with severe 2019 novel coronavirus pneumonia were retrospectively analyzed and relevant literatures were reviewed. Results At the beginning of the disease, the patient presented fever and dry cough, and later the disease progressed to dyspnea. Chest CT showed bilateral exudation of the lung. Lopinavir/ritonavir, IFN-a and immunoglobulin were given to the patient according to the expert group's opinion. The pneumonia was cured and the patient was discharged two weeks later. Conclusion Appropriate management strategies are effective on diagnosis and treatment of new coronavirus pneumonia.
ABSTRACT
Introduction: At the end of 2019, humanity was faced with the challenge of dealing with a new virus - coronavirus 2. Since the discovery of the virus, there have been more and more reports associating SARS-CoV-2 infection to various nervous system (NS) disorders. These disorders can be divided into processes that affect the central nervous system (CNS) and those that affect the peripheral nervous system (PNS).
ABSTRACT
The basic concept for use of convalescent plasma in COVID-19 is as a delivery system for viral neutralizing antibodies, that is to confer passive immunity. Given the fact that they do not have reliable targeted drugs or a vaccine yet, the option of convalescent plasma seems reasonable to boost the immune system of infected patients or susceptible population immediately. This is not a new concept, rather this has been utilized for over 100 years, even predating the discovery of antibiotics. Once it is confirmed that the proposed donor is no longer contagious, the next step would be to see if the donor has adequate levels of antibodies to donate. This can be done by measuring SARS-CoV-2 antibody levels to ensure adequate titers in the donor's circulation. The FDA recommends a SARS-CoV-2 neutralising antibody titer of at least 1:160 as an inclusion criterion for donor selection. If a compatible unit is not available, the FDA suggests that a titer of 1:80 may be considered acceptable. While waiting for an effective vaccine and / or antiviral agent against COVID-19, experimental therapies are currently being tested in clinical trials. So far, plasma therapy has provided encouraging results with no serious events. It is expected that an increasing use of convalescent plasma for the treatment of seriously ill patients and possibly earlier in the course of the disease and/or for prophylaxis in the coming months. The American Red Cross, the United States government, researchers at the Mayo Clinic, and many others across the country are now working hard to identify suitable donors and establish tests to confirm neutralizing antibodies in such a way that they timely. Since the antibody test is validated, it should help support the most effective use of convalescent plasma. Additionally, efforts are being made to continue the production of a COVID-19 immunoglobulin that could provide a more reliable, effective, and more available plasma-based therapy for this formidable virus.